From: Maternal adverse childhood experiences (ACEs) and DNA methylation of newborns in cord blood
Module (# CpGs) | KEGG | GO | ||||
---|---|---|---|---|---|---|
FDR | Pathway | Description | FDR | Pathway | Description | |
LightCyan1 (48) | – | – | – | – | – | – |
Blue (109,576) | 7.28 × 10–10 | hsa05014 | Amyotrophic lateral sclerosis | 9.79 × 10–158 | GO:0043231 (CC) | Intracellular membrane-bounded organelle |
 | 9.98 × 10–09 | hsa05016 | Huntington disease | 4.50 × 10–150 | GO:0043229 (CC) | Intracellular organelle |
 | 9.98 × 10–09 | hsa05022 | Pathways of neurodegeneration—multiple diseases | 2.35 × 10–138 | GO:0005622 (CC) | Intracellular anatomical structure |
 | 1.20 × 10–07 | hsa03040 | Spliceosome | 9.12 × 10–120 | GO:0005654 (CC) | Nucleoplasm |
 | 1.20 × 10–07 | hsa04144 | Endocytosis | 2.50 × 10–116 | GO:0043227 (CC) | Membrane-bounded organelle |
 | 1.20 × 10–07 | hsa04390 | Hippo signaling pathway | 5.08 × 10–114 | GO:0043226 (CC) | Organelle |
 | 1.46 × 10–07 | hsa03010 | Ribosome | 7.24 × 10–102 | GO:0005634 (CC) | Nucleus |
 | 2.96 × 10–07 | hsa05165 | Human papillomavirus infection | 3.06 × 10–100 | GO:0044260 (BP) | Cellular macromolecule metabolic process |
 | 5.62 × 10–07 | hsa05168 | Herpes simplex virus 1 infection | 4.11 × 10–90 | GO:0044237 (BP) | Cellular metabolic process |
 | 1.65 × 10–06 | hsa04110 | Cell cycle | 2.83 × 10–89 | GO:0005515 (MF) | Protein binding |
Pink (12,955) | 0.028 | hsa05020 | Prion disease | 4.95 × 10–23 | GO:0005654 (CC) | Nucleoplasm |
 | 0.040 | hsa03010 | Ribosome | 3.96 × 10–19 | GO:0003676 (MF) | Nucleic acid binding |
 | 0.040 | hsa03050 | Proteasome | 5.67 × 10–19 | GO:0034641 (BP) | Cellular nitrogen compound metabolic process |
 |  |  |  | 1.52 × 10–18 | GO:0006139 (BP) | Nucleobase-containing compound metabolic process |
 |  |  |  | 1.52 × 10–18 | GO:0044271 (BP) | Cellular nitrogen compound biosynthetic process |
 |  |  |  | 2.30 × 10–18 | GO:0070013 (CC) | Intracellular organelle lumen |
 |  |  |  | 2.71 × 10–18 | GO:0031981 (CC) | Nuclear lumen |
 |  |  |  | 2.71 × 10–18 | GO:0034645 (BP) | Cellular macromolecule biosynthetic process |
 |  |  |  | 5.37 × 10–18 | GO:0009059 (BP) | Macromolecule biosynthetic process |
 |  |  |  | 5.37 × 10–18 | GO:0031974 (CC) | Membrane-enclosed lumen |
SkyBlue4 (63) | – | – | – | – | – | – |
Salmon (2531) | 1.03 × 10–7 | hsa04659 | Th17 cell differentiation | 3.75 × 10–22 | GO:0001775 (BP) | Lymphocyte activation |
2.14 × 10–7 | hsa04060 | Cytokine–cytokine receptor interaction | 3.75 × 10–22 | GO:0046649 (BP) | T cell activation | |
1.01 × 10–6 | hsa04660 | T cell receptor signaling pathway | 5.89 × 10–22 | GO:0042110 (BP) | Leukocyte activation | |
2.21 × 10–5 | hsa04658 | Th1 and Th2 cell differentiation | 7.57 × 10–22 | GO:0045321 (BP) | Immune system process | |
5.19 × 10–5 | hsa04640 | Hematopoietic cell lineage | 8.86 × 10–21 | GO:0002376 (BP) | Immune response | |
1.4 × 10–4 | hsa05166 | Human T-cell leukemia virus 1 infection | 8.06 × 10–19 | GO:0006955 (BP) | adaptive immune response | |
1.4 × 10–4 | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.33 × 10–15 | GO:0002250 (BP) | T cell differentiation | |
0.001 | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.63 × 10–13 | GO:0030217 (BP) | Immune effector process | |
0.003 | hsa04064 | NF-kappa B signaling pathway | 3.64 × 10–13 | GO:0002252 (BP) | Regulation of immune system process | |
0.003 | hsa05170 | Human immunodeficiency virus 1 infection | 1.49 × 10–12 | GO:0002682 (BP) | Lymphocyte differentiation | |
SaddleBrown (94) | – | – | – | 0.003 | GO:0048704 (BP) | Embryonic skeletal system morphogenesis |
 |  |  | 0.003 | GO:0048706 (BP) | Embryonic skeletal system development | |
 |  |  | 0.007 | GO:0009952 (BP) | Anterior/posterior pattern specification | |
 |  |  | 0.011 | GO:0048705 (BP) | Skeletal system morphogenesis | |
 |  |  | 0.020 | GO:0048652 (BP) | Embryonic organ morphogenesis | |
 |  |  | 0.024 | GO:0003002 (BP) | Regionalization | |
 |  |  | 0.047 | GO:0007389 (BP) | Pattern specification process | |
 |  |  | 0.047 | GO:0048568 (BP) | Embryonic organ development | |
RoyalBlue (296) | – | – | – | – | – | – |
Magenta (3363) | – | – | – | 7.45 × 10–6 | GO:0002376 (BP) | Immune system process |
 |  |  | 4.76 × 10–5 | GO:0006955 (BP) | Immune response | |
 |  |  | 0.004 | GO:0006954 (BP) | Inflammatory response | |
 |  |  | 0.006 | GO:0001775 (BP) | Cell activation | |
 |  |  | 0.03 | GO:0002366 (BP) | Leukocyte activation involved in immune response | |
 |  |  | 0.03 | GO:0006887 (BP) | Exocytosis | |
 |  |  | 0.03 | GO:0030097 (BP) | Hemopoiesis | |
 |  |  | 0.03 | GO:0045055 (BP) | Regulated exocytosis | |
 |  |  | 0.03 | GO:0048534 (BP) | Hematopoietic or lymphoid organ development | |
 |  |  | 0.032 | GO:0045321 (BP) | Leukocyte activation | |
MidnightBlue (822) | 1.69 × 10–7 | hsa04650 | Natural killer cell-mediated cytotoxicity | 0.008 | GO:0002682 (BP) | Regulation of immune system process |
0.016 | hsa04660 | T cell receptor signaling pathway | 0.013 | GO:0035556 (BP) | Intracellular signal transduction | |
0.016 | hsa05135 | Yersinia infection | 0.019 | GO:0006955 (BP) | Immune response | |
0.040 | hsa05332 | Graft-versus-host disease | 0.022 | GO:0002228 (BP) | Natural killer cell-mediated immunity | |
 |  |  | 0.033 | GO:0050776 (BP) | Regulation of immune response | |
 |  |  | 0.038 | GO:0001906 (BP) | Cell killing | |
 |  |  | 0.038 | GO:0006952 (BP) | Defense response | |
 |  |  | 0.038 | GO:0007159 (BP) | Leukocyte cell–cell adhesion | |
 |  |  | 0.039 | GO:0006909 (BP) | Phagocytosis | |
 |  |  | 0.039 | GO:0046649 (BP) | Lymphocyte activation | |
Brown (91,675) | 0.032 | hsa04012 | ErbB signaling pathway | 0.002 | GO:0042995 (CC) | Cell projection |
 | 0.032 | hsa04921 | Oxytocin signaling pathway | 0.002 | GO:0043167 (MF) | Ion binding |
 |  |  |  | 0.009 | GO:0120025 (CC) | Plasma membrane-bounded cell projection |
 |  |  |  | 0.030 | GO:0046873 (MF) | Metal ion transmembrane transporter activity |
Turquoise (84,323) | 0.001 | hsa04020 | Calcium signaling pathway | 9.94 × 10–42 | GO:0071944 (CC) | Cell periphery |
0.001 | hsa04072 | Phospholipase D signaling pathway | 2.58 × 10–32 | GO:0005886 (CC) | Plasma membrane | |
0.001 | hsa05150 | Staphylococcus aureus infection | 3.41 × 10–19 | GO:0031224 (CC) | Intrinsic component of membrane | |
0.001 | hsa05414 | Dilated cardiomyopathy | 1.06 × 10–15 | GO:0016021 (CC) | Integral component of membrane | |
0.003 | hsa05410 | Hypertrophic cardiomyopathy | 6.08 × 10–14 | GO:0005261 (MF) | Cation channel activity | |
0.007 | hsa04060 | Cytokine–cytokine receptor interaction | 1.70 × 10–13 | GO:0046873 (MF) | Metal ion transmembrane transporter activity | |
0.007 | hsa04080 | Neuroactive ligand-receptor interaction | 2.07 × 10–13 | GO:0015267 (MF) | Channel activity | |
0.007 | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.39 × 10–13 | GO:0022803 (MF) | Passive transmembrane transporter activity | |
0.007 | hsa04512 | ECM-receptor interaction | 5.09 × 10–13 | GO:0031226 (CC) | Intrinsic component of plasma membrane | |
0.007 | hsa04975 | Fat digestion and absorption | 3.09 × 10–12 | GO:0005216 (MF) | Ion channel activity | |
Ivory (85) | – | – | – | 5.91 × 10–28 | GO:0007156 (BP) | Homophilic cell adhesion via plasma membrane adhesion molecules |
 |  |  |  | 2.00 × 10–24 | GO:0098742 (BP) | Cell–cell adhesion via plasma-membrane adhesion molecules |
 |  |  |  | 1.50 × 10–17 | GO:0005509 (MF) | Calcium ion binding |
 |  |  |  | 5.37 × 10–16 | GO:0098609 (BP) | Cell–cell adhesion |
 |  |  |  | 2.27 × 10–12 | GO:0007155 (BP) | Cell adhesion |
 |  |  |  | 2.27 × 10–12 | GO:0022610 (BP) | Biological adhesion |
 |  |  |  | 1.13 × 10–11 | GO:0005887 (CC) | Integral component of plasma membrane |
 |  |  |  | 2.18 × 10–11 | GO:0031226 (CC) | Intrinsic component of plasma membrane |
 |  |  |  | 3.51 × 10–04 | GO:0046872 (MF) | Metal ion binding |
 |  |  |  | 4.25 × 10–04 | GO:0043169 (MF) | Cation binding |
Sienna4 (33) | – | – | – | – | – | – |
DarkOliveGreen (72) | – | – | – | – | – | – |
Yellow3 (59) | – | – | – | – | – | – |